Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Keith B Nolop"'
Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate
Autor:
Mark L. Vanderwalker, Keith B Nolop, Anjuli Nayak, David F. Graft, Judy E. Harrison, Frank J. Picone, Robert A. Nathan, Tahir Ahmed, James D. Wolfe, Michael S. Lawrence
Publikováno v:
Annals of Allergy, Asthma & Immunology. 86:203-210
Mometasone furoate (MF) is a new inhaled glucocorticoid administered by dry powder inhaler (DPI).MF-DPI was evaluated for safety and efficacy and compared with placebo DPI and beclomethasone dipropionate (BDP) administered by metered dose inhaler (MD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb379d0d2e428a0a4892d0b0b6f1c69
https://doi.org/10.1016/s1081-1206(10)62692-0
https://doi.org/10.1016/s1081-1206(10)62692-0
Autor:
Michael Noonan, D R Webb, J P Karpel, George W. Bensch, Barry N. Lutsky, Keith B Nolop, Joe W. Ramsdell
Publikováno v:
Annals of Allergy, Asthma & Immunology. 86:36-43
Background Once-daily dosing with an effective inhaled corticosteroid (ICS) would likely enhance compliance and, therefore, aid in the management of asthma. Objective Several once-daily dosing regimens of mometasone furoate (MF) administered by dry p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d081745decf7eb77adb8e0fb2c379fd
https://doi.org/10.1016/s1081-1206(10)62353-8
https://doi.org/10.1016/s1081-1206(10)62353-8
Autor:
William R. Lumry, M. Karetzky, Judy E. Harrison, L. Repsher, Guy A. Settipane, Paul Chervinsky, A.F. Finn, J.P. Kemp, A. Wanderer, David S. Pearlman, L.M. Mendelson, Keith B Nolop, Harold S. Nelson, R. B. Berkowitz, C. LaForce, David I. Bernstein, G.N. Gross, J.C. Selner, Cuss Francis M, P. Ratner, D.J. Dvorin, A.T. Segal, G. Rachelefsky
Publikováno v:
Respiratory Medicine. 93:603-612
A new formulation of mometasone furoate (MF) for administration by dry powder inhaler (DPI) was evaluated for the treatment of asthma. A 12-week, double-blind, placebo-controlled dose-ranging study compared the efficacy and safety of three doses of M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29aac831ea9060c9332755be2dfb1da5
https://doi.org/10.1016/s0954-6111(99)90099-9
https://doi.org/10.1016/s0954-6111(99)90099-9
Autor:
Julius van Bavel, George E. Stewart, Keith B. Nolop, Jay Grossman, Albert F. Finn, Eric J. Schenkel, David P. Skoner, Nathan Segall, Robert J. Dockhorn, Eli O. Meltzer, Ita Tripathy, Edwin A. Bronsky, Michael E. Ruff, Frank C. Hampel, Paul H. Ratner, Barbara Mesarina-Wicki, William E. Berger, Donald J. Dvorin, Robert Anolik, Allen T. Segal, Stanley P. Galant, Robert B. Berkowitz
Publikováno v:
Journal of Allergy and Clinical Immunology. 104:107-114
Background: The efficacy and safety of mometasone furoate aqueous nasal spray (MFNS; Nasonex) 200 μg once daily for the treatment and prophylaxis of seasonal allergic rhinitis (SAR) and treatment of perennial rhinitis have been demonstrated in adult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e4e3f6906729e9f39706f9a5ab8a9df
https://doi.org/10.1016/s0091-6749(99)70121-1
https://doi.org/10.1016/s0091-6749(99)70121-1
Autor:
Andrew Pedinoff, R. B. Berkowitz, A. R. Rooklin, B. Mesarina-Wicki, C. LaForce, C. R. V. Damaraju, David I. Bernstein, Keith B Nolop
Publikováno v:
Allergy. 54:64-69
Background:Mometasone furoate nasal spray (MFNS, NASONEX®), is a new synthetic corticosteroid with considerable efficacy in the treatment of seasonal and perennial rhinitis and less than 0.1% systemic absorption. This study was designed to evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::808f096bdfe7ae0eb7a8726f3c8be6d8
https://doi.org/10.1034/j.1398-9995.1999.00713.x
https://doi.org/10.1034/j.1398-9995.1999.00713.x
Publikováno v:
Annals of Allergy, Asthma & Immunology. 79:370-378
Background Mometasone furoate (Nasonex), in a new once daily aqueous nasal spray formulation, has been shown to be as effective and well tolerated as twice daily beclomethasone dipropionate aqueous nasal spray in treating symptoms of seasonal allergi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6377144134fdcbac5616265fc962bf3
https://doi.org/10.1016/s1081-1206(10)63030-x
https://doi.org/10.1016/s1081-1206(10)63030-x
Publikováno v:
Chest. 112:34-39
Study objective To compare the efficacy and safety of a double-strength formulation of beclomethasone dipropionate (BDP 84) metered-dose inhaler (MDI) with that of beclomethasone dipropionate (BDP 42) MDI in the treatment of chronic asthma. Design A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e06e8859c70863e3e5bd6e024873d5d
https://doi.org/10.1378/chest.112.1.34
https://doi.org/10.1378/chest.112.1.34
Autor:
Gordon Sussman, Jouko Suonpää, Michel A. Drouin, William H. Yang, Mattheus Roovers, Paul Van Cauwenberge, Peter Clement, Royce Darnell, Bernard Bertrand, K. Y. Tan, Keith B Nolop, Jacques Hébert, Jorge Mazza, Kjell Dalby, Göran Karlsson, Jensen Peder K, Thomas-Matthias Ernst, Pirkko Ruoppi, Martin A. Stern, Kam Tse, Michel Seppey, Barry N. Lutsky, George Luciuk, Prabowo Widjaja
Publikováno v:
Annals of Allergy, Asthma & Immunology. 77:153-160
Background: Perennial allergic rhinitis is chronic and persistent, may lead to a constellation of secondary complaints including sinusitis, mouth-breathing, and some symptoms resembling a permanent cold, and often requires constant medical interventi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4de55d22c340a4f1e49fcbd5bd348d4
https://doi.org/10.1016/s1081-1206(10)63502-8
https://doi.org/10.1016/s1081-1206(10)63502-8
Autor:
D. Robert Webb, Stuart M. Garay, Jeffrey Leflein, Joe W. Ramsdell, Michael Noonan, J Grossman, William Berger, George W. Bensch, Anthony R. Rooklin, David F. Graft, Arthur C. DeGraff, Judy E. Harrison, Richard G. Gower, Lucy Shneyer, Evangelo Frigas, Keith B. Nolop, Jill P. Karpel, Eric J. Schenkel, Robert A. Nathan, Bernard Silverman, David I. Bernstein, Edwin A. Bronsky, Timothy J. Craig, James E. Fish
Publikováno v:
The Journal of allergy and clinical immunology. 106(5)
Inhaled corticosteroid therapy in severe persistent asthma has been shown to reduce or eliminate oral corticosteroid (OCS) use while retaining effective asthma control.We sought to evaluate the ability of mometasone furoate (MF) delivered by means of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::134121f49160f2bf61080fc441564d59
https://pubmed.ncbi.nlm.nih.gov/11080706
https://pubmed.ncbi.nlm.nih.gov/11080706
Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma
Autor:
Charles H. Banov, David S. Pearlman, Anjuli Nayak, Judy E. Harrison, Anthony T. Scardella, Gregory Gottschlich, Bernard Silverman, Alan B. Goldsobel, Barry K. Feinstein, Michael S. Lawrence, Bruce F. Friedman, Eric J. Schenkel, William R. Lumry, Allen T. Segal, Robert J. Lapidus, Zev M. Munk, Lucy Shneyer, Kathy L. Lampl, Anthony A. Floreani, Nathan Segall, Paul J. Hannaway, Jonathan Corren, Keith B Nolop
Publikováno v:
Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 84(4)
Background Although inhaled glucocorticoids are recommended for all stages of persistent asthma, compliance with long-term therapy is often poor, leading to significant morbidity and mortality. A simplified, once-daily dosing regimen may foster impro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0725b33ebb94d295db62a97a9b8fe4cc
https://pubmed.ncbi.nlm.nih.gov/10795650
https://pubmed.ncbi.nlm.nih.gov/10795650